{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:02:41Z","timestamp":1789938161530,"version":"4.0.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","award":["213727"],"award-info":[{"award-number":["213727"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004257","name":"Helse Vest RHF","doi-asserted-by":"publisher","award":["F-12506"],"award-info":[{"award-number":["F-12506"]}],"id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research: Cognition"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.scog.2026.100463","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:24:34Z","timestamp":1789629874000},"page":"100463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical insight in schizophrenia: Time-specific associations with symptoms, cognition and antipsychotic mechanisms"],"prefix":"10.1016","volume":"47","author":[{"given":"Lena Antonsen","family":"Stabell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune Andreas","family":"Kroken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else-Marie","family":"L\u00f8berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Joa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solveig Kl\u00e6bo","family":"Reitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rettenbacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Gjestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.scog.2026.100463_bb0005","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1192\/bjp.189.3.204","article-title":"Insight in psychosis and neuropsychological function: Meta-analysis","volume":"189","author":"Aleman","year":"2006","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.scog.2026.100463_bb0010","series-title":"Insight and Psychosis: Awareness of Illness in Schizophrenia and Related Disorders","author":"Amador","year":"2004"},{"issue":"1","key":"10.1016\/j.scog.2026.100463_bb0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0193-953X(05)70359-2","article-title":"Psychopathologic domains and insight in schizophrenia","volume":"21","author":"Amador","year":"1998","journal-title":"Psychiatr. Clin. N. Am."},{"key":"10.1016\/j.scog.2026.100463_bb0020","article-title":"Cognitive change and antipsychotic medications: results from a pragmatic rater-blind RCT","volume":"26","author":"Anda","year":"2021","journal-title":"Schizophr. Res. Cogn."},{"issue":"1","key":"10.1016\/j.scog.2026.100463_bb0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1076\/clin.12.1.43.1726","article-title":"Hopkins verbal learning test \u2013 revised: normative data and analysis of inter-form and test-retest reliability","volume":"12","author":"Benedict","year":"1998","journal-title":"Clin. Neuropsychol."},{"issue":"1","key":"10.1016\/j.scog.2026.100463_bb0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.psychres.2014.03.022","article-title":"Effects of antipsychotic drugs on insight in schizophrenia","volume":"218","author":"Bianchini","year":"2014","journal-title":"Psychiatry Res."},{"issue":"4","key":"10.1016\/j.scog.2026.100463_bb0035","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.apnu.2020.06.002","article-title":"A qualitative study of medication adherence amongst people with schizophrenia","volume":"34","author":"Clifford","year":"2020","journal-title":"Arch. Psychiatr. Nurs."},{"issue":"2","key":"10.1016\/j.scog.2026.100463_bb0040","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1192\/bja.2021.39","article-title":"Partial agonists of dopamine receptors: receptor theory and the dopamine hypothesis of psychosis","volume":"29","author":"Cookson","year":"2023","journal-title":"BJPsych Advances"},{"issue":"8","key":"10.1016\/j.scog.2026.100463_bb0045","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.euroneuro.2015.04.003","article-title":"Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies","volume":"25","author":"Czobor","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.scog.2026.100463_bb0050","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1192\/bjp.156.6.798","article-title":"Insight and psychosis","volume":"156","author":"David","year":"1990","journal-title":"Br. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.scog.2026.100463_bb0055","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40263-015-0278-3","article-title":"Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism","volume":"29","author":"de Bartolomeis","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.scog.2026.100463_bb0060","series-title":"Delis-Kaplan Executive Function System (D\u2013KEFS)","author":"Delis","year":"2001"},{"issue":"1","key":"10.1016\/j.scog.2026.100463_bb0065","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12888-021-03681-6","article-title":"Factors influencing medication adherence among patients with severe mental disorders from the perspective of mental health professionals","volume":"22","author":"Deng","year":"2022","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.scog.2026.100463_bb0070","series-title":"Discovering Statistics Using SPSS","author":"Field","year":"2024"},{"key":"10.1016\/j.scog.2026.100463_bb0075","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.psychres.2017.01.090","article-title":"Insight into illness and its relationship to illness severity, cognition and estimated antipsychotic dopamine receptor occupancy in schizophrenia: an antipsychotic dose reduction study","volume":"251","author":"Gerretsen","year":"2017","journal-title":"Psychiatry Res."},{"issue":"15","key":"10.1016\/j.scog.2026.100463_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512374","article-title":"Insights into the mechanism of action of antipsychotic drugs derived from animal models: standard of care versus novel targets","volume":"24","author":"Grace","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.scog.2026.100463_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.111688","article-title":"To adjust, or not to adjust, for multiple comparisons","volume":"180","author":"Hooper","year":"2025","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.scog.2026.100463_bb0090","series-title":"IBM SPSS Statistics for Windows 29 ed","author":"IBM","year":"2022"},{"issue":"11","key":"10.1016\/j.scog.2026.100463_bb0095","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S2215-0366(20)30341-2","article-title":"Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial","volume":"7","author":"Johnsen","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.scog.2026.100463_bb0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1176\/appi.ajp.160.1.13","article-title":"Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia","volume":"160","author":"Kapur","year":"2003","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.scog.2026.100463_bb0105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.scog.2026.100463_bb0110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0165-1781(88)90038-8","article-title":"Reliability and validity of the positive and negative syndrome scale for schizophrenics","volume":"23","author":"Kay","year":"1988","journal-title":"Psychiatry Res."},{"issue":"2\u20133","key":"10.1016\/j.scog.2026.100463_bb0115","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","article-title":"The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery","volume":"68","author":"Keefe","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.scog.2026.100463_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.05.011","article-title":"Insight and medication adherence in schizophrenia: an analysis of the CATIE trial","volume":"168","author":"Kim","year":"2020","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.scog.2026.100463_bb0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41537-023-00347-y","article-title":"Cortical thinning in relation to impaired insight into illness in patients with treatment resistant schizophrenia","volume":"9","author":"Kim","year":"2023","journal-title":"Schizophrenia"},{"key":"10.1016\/j.scog.2026.100463_bb0130","series-title":"Principles and Practice of Structural Equation Modeling","author":"Kline","year":"2011"},{"issue":"5","key":"10.1016\/j.scog.2026.100463_bb0135","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/JCP.0b013e3182983ffa","article-title":"Estimating dopamine D\u2082 receptor occupancy for doses of 8 antipsychotics: a meta-analysis","volume":"33","author":"Lako","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5\u20136","key":"10.1016\/j.scog.2026.100463_bb0140","first-page":"10","article-title":"Anosognosia in schizophrenia: hidden in plain sight","volume":"11","author":"Lehrer","year":"2014","journal-title":"Innovations in clinical neuroscience"},{"issue":"6","key":"10.1016\/j.scog.2026.100463_bb0145","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/schbul\/sbm002","article-title":"Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review","volume":"33","author":"Lincoln","year":"2007","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.scog.2026.100463_bb0150","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1192\/bjp.2024.173","article-title":"Is too much insight bad for you?","volume":"225","author":"Lopez-Morinigo","year":"2024","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.scog.2026.100463_bb0155","article-title":"Changes in insight and outcome over the early course of first-episode psychosis. The OPTiMiSE trial","volume":"45","author":"Lopez-Morinigo","year":"2026","journal-title":"Schizophr. Res. Cogn."},{"issue":"1","key":"10.1016\/j.scog.2026.100463_bb0160","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/wps.20508","article-title":"Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments","volume":"17","author":"Lysaker","year":"2018","journal-title":"World Psychiatry"},{"issue":"1","key":"10.1016\/j.scog.2026.100463_bb0165","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.euroneuro.2016.10.004","article-title":"The impact of second generation antipsychotics on insight in schizophrenia: results from 14 randomized, placebo controlled trials","volume":"27","author":"Mattila","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.scog.2026.100463_bb0170","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/schbul\/sbn067","article-title":"Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia","volume":"35","author":"Mohamed","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"7","key":"10.1016\/j.scog.2026.100463_bb0175","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00406-008-0809-8","article-title":"Insight, cognitive dysfunction and symptomatology in schizophrenia","volume":"258","author":"Monteiro","year":"2008","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"8","key":"10.1016\/j.scog.2026.100463_bb0180","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s00213-016-4234-9","article-title":"An investigation into aripiprazole\u2019s partial D\u2082 agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers","volume":"233","author":"Murphy","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.scog.2026.100463_bb0185","series-title":"MPlus","author":"Muth\u00e9n","year":"2024"},{"issue":"1","key":"10.1016\/j.scog.2026.100463_bb0190","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.schres.2013.11.033","article-title":"Relationship between cognition, clinical and cognitive insight in psychotic disorders: a review and meta-analysis","volume":"152","author":"Nair","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.scog.2026.100463_bb0195","series-title":"Longitudinal Structural Equation Modeling","author":"Newsom","year":"2015"},{"issue":"5","key":"10.1016\/j.scog.2026.100463_bb0200","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10459-010-9222-y","article-title":"Likert scales, levels of measurement and the \u201claws\u201d of statistics","volume":"15","author":"Norman","year":"2010","journal-title":"Adv. Health Sci. Educ. Theory Pract."},{"key":"10.1016\/j.scog.2026.100463_bb0205","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pnpbp.2018.08.033","article-title":"The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: an analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data","volume":"89","author":"Ozzoude","year":"2019","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.scog.2026.100463_bb0210","series-title":"Measurement, Design, and Analysis","author":"Pedhazur","year":"1991"},{"issue":"6","key":"10.1016\/j.scog.2026.100463_bb0220","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.euroneuro.2015.02.012","article-title":"Differential effects of antipsychotic drugs on insight in first episode schizophrenia: data from the European first-episode schizophrenia trial (EUFEST)","volume":"25","author":"Pijnenborg","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.scog.2026.100463_bb0215","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.schres.2018.10.013","article-title":"Changes in insight over the first 24 months of treatment in schizophrenia spectrum disorders","volume":"206","author":"Phahladira","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.scog.2026.100463_bb0225","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.neubiorev.2020.06.022","article-title":"Brain areas associated with clinical and cognitive insight in psychotic disorders: a systematic review and meta-analysis","volume":"116","author":"Pijnenborg","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"2","key":"10.1016\/j.scog.2026.100463_bb0230","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/acps.12138","article-title":"Insight change in psychosis: relationship with neurocognition, social cognition, clinical symptoms and phase of illness","volume":"129","author":"Quee","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.scog.2026.100463_bb0235","series-title":"Trail Making Test: Manual for Administration and Scoring","author":"Reitan","year":"1992"},{"issue":"3","key":"10.1016\/j.scog.2026.100463_bb0240","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/schbul\/sbr189","article-title":"Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data","volume":"39","author":"Sakurai","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.scog.2026.100463_bb0245","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1017\/S0033291797006296","article-title":"A comparative study of insight scales and their relationship to psychopathological and clinical variables","volume":"28","author":"Sanz","year":"1998","journal-title":"Psychol. Med."},{"issue":"8","key":"10.1016\/j.scog.2026.100463_bb0250","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.eurpsy.2012.01.001","article-title":"Insight in schizophrenia\u2013course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorder","volume":"27","author":"Schennach","year":"2012","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.scog.2026.100463_bb0255","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2025.11.005","article-title":"Does insight improve during the course of psychosis?","volume":"287","author":"Seif","year":"2025","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.scog.2026.100463_bb0260","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis","volume":"28","author":"Siafis","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.scog.2026.100463_bb0265","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s12888-023-04981-9","article-title":"Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial","volume":"23","author":"Stabell","year":"2023","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.scog.2026.100463_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2026.116948","article-title":"Levels of and changes in psychosis symptoms and clinical insight: exploring the impact of differential antipsychotic mechanisms","volume":"358","author":"Stabell","year":"2026","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.scog.2026.100463_bb0275","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.schres.2020.03.038","article-title":"Relationship of poor insight to neurocognition, social cognition, and psychiatric symptoms in schizophrenia: a meta-analysis","volume":"220","author":"Subotnik","year":"2020","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.scog.2026.100463_bb0280","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s007020200033","article-title":"Partial dopamine agonists in the treatment of psychosis","volume":"109","author":"Tamminga","year":"2002","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"8","key":"10.1016\/j.scog.2026.100463_bb0285","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2174\/1570159X15666170413115754","article-title":"Aripiprazole, a drug that displays partial agonism and functional selectivity","volume":"15","author":"Tuplin","year":"2017","journal-title":"Curr. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.scog.2026.100463_bb0290","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/JCP.0b013e3182214aad","article-title":"Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis","volume":"31","author":"Uchida","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.scog.2026.100463_bb0295","series-title":"Wechsler Adult Intelligence Scale--Fourth Edition (WAIS-IV)","author":"Wechsler","year":"2008"},{"key":"10.1016\/j.scog.2026.100463_bb0300","series-title":"ICD-10: international statistical classification of diseases and related health problems: tenth revision","author":"World Health","year":"2004"},{"issue":"6","key":"10.1016\/j.scog.2026.100463_bb0305","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s40263-020-00713-9","article-title":"Adherence to Oral antipsychotics measured by electronic adherence monitoring in schizophrenia: a systematic review and Meta-analysis","volume":"34","author":"Yaegashi","year":"2020","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.scog.2026.100463_bb0310","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0893-133X(02)00304-4","article-title":"Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride","volume":"27","author":"Yokoi","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"2\u20133","key":"10.1016\/j.scog.2026.100463_bb0315","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.schres.2013.08.001","article-title":"Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review","volume":"152","author":"Zipursky","year":"2014","journal-title":"Schizophr. Res."}],"container-title":["Schizophrenia Research: Cognition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215001326000466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215001326000466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T20:09:27Z","timestamp":1789934967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2215001326000466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":63,"alternative-id":["S2215001326000466"],"URL":"https:\/\/doi.org\/10.1016\/j.scog.2026.100463","relation":{},"ISSN":["2215-0013"],"issn-type":[{"value":"2215-0013","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical insight in schizophrenia: Time-specific associations with symptoms, cognition and antipsychotic mechanisms","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research: Cognition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.scog.2026.100463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100463"}}